1

Abstract

The paper analyzes the effectiveness of a new class of medications — CDK4/6 cyclin-dependent kinases inhibitors and discover the mechanism of its action. The article describes the general results of studies on palbociclib, ribociclib and abemaciclib* for the first- and subsequent-line of the therapy of HR-positive/HER2-negative metastatic breast cancer. The profile of adverse events of approved CDK4/6 inhibitors are considered. The combination of CDK4/6 inhibitors with endocrine therapy was shown to have benefits in survival, potentiality to reduce hormone resistance and great perspectives to improve clinical results of hormone receptor-positive metastatic breast cancer.